Initiation of Phase 3 FORZETTO Clinical Trial Testing Zeleciment Rostudirsen in Duchenne Muscular Dystrophy by Madaline Spencer| Published on: Aug 4, 2026

Initiation of Phase 3 FORZETTO Clinical Trial Testing Zeleciment Rostudirsen in Duchenne Muscular Dystrophy by Madaline Spencer| Published on: Aug 4, 2026 Doug Kerr, MD, PhD, MBA, Chief Medical Officer of Dyne Therapeutics, discusses the initiation of the phase 3 FORZETTO trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), in individuals with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. https://checkrare.com/initiation-of-phase-3-forzetto-clinical-trial-testing-zeleciment-rostudirsen-in-duchenne-muscular-dystrophy/